Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7533459 | 0.91 | ALOX5 (0.52) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL21494459 | 0.89 | PDE4D (0.59) | KMT2AMEN1ALOX5OR51E2PDE4D | |
| Phenyl Propionic Acid SCHEMBL28541899 | 0.89 | KMT2A (0.63) | KMT2AMEN1ALDH1A1ALOX5 | |
| SCHEMBL2275943 | 0.87 | KMT2A (0.51) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL8113403 | 0.87 | ATM (0.57) | KMT2AMEN1CA12CA1CA2 | |
| Dihydroferulic Acid Methyl Ester SCHEMBL490876 | 0.87 | ALOX5 (0.77) | ALDH1A1ALOX5OR51E2 | |
| SCHEMBL18744079 | 0.87 | ALOX5 (0.55) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL28287006 | 0.87 | CYP19A1 (0.65) | KMT2AMEN1ALOX5OR51E2 | |
| SCHEMBL18224202 | 0.86 | ALOX5 (0.54) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL10307841 | 0.86 | ALOX5 (0.77) | KMT2AMEN1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449167-B2 | Polyamine derivative medicinal salt and preparation method and use | Chongqing Antixin Biotechnology Co., LTD. (CN) | 2019-10-22 | — | — | US | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| CN-100372836-C | Novel immunotherapeutic imides/amides | CELGENE CORP (US) | 2008-03-05 | — | — | CN | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| CN-1254333-A | Immunotherapeutic imides/amides | CELGENE CORP (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0703919-B1 | PHOSPHOSUCCINIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1998-09-02 | — | — | EP | disclosed |
| US-5683994-A | BONE DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-11-04 | — | — | US | disclosed |
| US-5414108-A | From a Meldrum's acid derivative | BIOGAL GYOGYSZERGRAR (HU) | 1995-05-09 | — | — | US | disclosed |
| US-5350872-A | Decyclization and decarboxylation of a 1,3-dioxane-4,6-dione | BIOGAL GYOGYSZERGRAR (HU) | 1994-09-27 | — | — | US | disclosed |
| EP-0297733-A2 | Pharmaceutical compositions comprising catecholic butanes | BLOCK DRUG COMPANY, INC. (US) | 1989-01-04 | — | — | EP | disclosed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| EP-0288534-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. | CHEMEX PHARMACEUTICALS INC (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988003806-A1 | PHARMACOLOGICALLY ACTIVE COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| WO-1988003026-A1 | COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-05-05 | — | — | WO | disclosed |
| US-4733002-A | Lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1988-03-22 | — | — | US | disclosed |
| EP-0163270-A2 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1985-12-04 | — | — | EP | disclosed |
| US-4188338-A | ANTICOAGULANTS | AKZONA INCORPORATED (US) | 1980-02-12 | — | — | US | disclosed |
| US-4173652-A | ANTICOAGULANTS | AKZONA INCORPORATED (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449167-B2 | Polyamine derivative medicinal salt and preparation method and use | SRM, TLR9, SELP | KMT2A 695/4885MEN1 1883/4885CA12 4463/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | KMT2A 4680/4885MEN1 1408/4885CA12 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.